UPDATED 2009: 2009 locations of publicly funded PET scanners and Cyclotrons in Canada 2008 locations of publicly funded PET scanners and Cyclotrons in Canada
UPDATED 2009: 2009 locations of publicly funded PET scanners and Cyclotrons in Canada 2008 locations of publicly funded PET scanners and Cyclotrons in Canada
This search tool includes Canadian health technology assessment (HTA) agencies and organizations that are involved in systematic reviews, meta-analyses, and health economics. To access the Canadian sites that CADTH has included as part of this search tool, please see the list below. If you are an HTA producer and would like to be included as par...
Welcome to the eleventh issue of Health Technology Update. This second newsletter of 2009 brings you information on a variety of medical technologies. The issue’s feature article addresses the current global crisis in isotope production in medical imaging. New and emerging technologies and practices are currently being identified that may play ...
The Policy Forum was created in response to the Health Technology Strategy 1.0, and the subsequent Implementation Strategy, approved by the Conference of Deputy Ministers in May 2004 and April 2005 respectively. The mandate of the Policy Forum is to provide federal, provincial, and territorial jurisdictions with opportunities to share info...
The Policy Forum Terms of Reference have been derived from the Health Technology Strategy 1.0, and were approved by the CADTH Board of Directors in October 2006.
2010 Award of Excellence Dr. Brian O’Rourke, President and CEO of the Canadian Agency for Drugs and Technologies in Health (CADTH), is pleased to announce that Dr. Andreas Laupacis, MD, MSc, FRCPC, is the inaugural recipient of the Jill M. Sanders Award of Excellence in Health Technology Assessment (HTA). “Dr. Laupacis is a nationally and inte...
CADTH is committed to continuous improvement and transparency. Here you will find evaluations of CADTH and specific CADTH initiatives, as well as responses to the evaluations. 2016 Science-Metrix Evaluation of CADTH 2016 Science-Metrix Evaluation of CADTH - Management Response 2016 Application Fees Administrative Review 2015 MEDLIOR H...
As was announced in May 2014, CADTH will be implementing an application fee for manufacturer applications filed with the CADTH pan-Canadian Oncology Drug Review (pCODR). It is proposed that all manufacturer applications with a Health Canada Notice of Compliance (NOC) or Notice of Compliance with conditions (NOC/c) date of April 1, 2015 or la...
CADTH operates two pan-Canadian drug review processes: the CADTH pan-Canadian Oncology Drug Review (pCODR), which deals specifically with cancer drugs, and the CADTH Common Drug Review (CDR), which deals with other drugs. Both pCODR and CDR are designed to bring consistency and clarity to the assessment of drugs in Canada by reviewing clinical...